Does borderline kidney allograft rejection always require treatment?

• Published in: Transplantation Vol. 90; no. 4; p. 427
• Main Authors: Németh, Dorottya, Ovens, Jörg, Opelz, Gerhard, Sommerer, Claudia, Döhler, Bernd, Becker, Luis E, Gross, Marie-Luise, Waldherr, Rüdiger, Mieth, Markus, Sadeghi, Mahmoud, Schmidt, Jan, Langer, Robert M, Zeier, Martin, Süsal, Caner
• Format: Journal Article
• Language: English
• Published: United States 27.08.2010
• Subjects: Adult; DNA Primers; Female; Forkhead Transcription Factors - blood; Forkhead Transcription Factors - genetics; Graft Rejection - drug therapy; Histocompatibility Testing; Humans; Immunosuppressive Agents - therapeutic use; Kidney Transplantation - immunology; Kidney Transplantation - pathology; Male; Middle Aged; Operon - genetics; Polymerase Chain Reaction; T-Lymphocytes, Regulatory - pathology
• ISSN: 1534-6080
• DOI: 10.1097/TP.0b013e3181e81b16

Borderline rejection (Bord-R) is a frequent diagnosis in renal transplantation, and there is increasing evidence that regulatory T lymphocytes are involved in its pathogenesis. Current histopathologic practice does not differentiate between graft-protecting and -damaging T lymphocytes, and patients with Bord-R routinely receive rejection treatment. We analyzed Treg-associated forkhead box P3 (Foxp3) gene expression in Bord-R and more severe forms of acute rejection episodes (ARE). Foxp3 transcripts were measured in 520 serial peripheral blood samples from 177 kidney graft recipients obtained during the first 20 days posttransplantation. The highest Foxp3 transcripts were observed in patients with Bord-R or without rejection and the lowest in patients with ARE. Patients with Bord-R on posttransplant days 5 to 7 showed an increased Foxp3 transcript level of 156%, which increased to 302% by posttransplant days 14 to 16. In contrast, patients with ARE demonstrated significantly lower Foxp3 gene expression than that observed in Bord-R, nonrejectors, or acute tubular necrosis patients (P=0.001, P<0.001, and P=0.005, respectively, on days 11-13). Acute tubular necrosis patients demonstrated intermediately high Foxp3 gene expression. Our data indicate that increased Treg activity in peripheral blood is a frequent feature of Bord-R. This finding questions the appropriateness of rejection treatment in all patients with the histopathologic diagnosis "Bord-R".